Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | AGER | Q15109 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 7/20 | 0.45 |
| ▸ | RAB9A | P51151 | 7/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186009 | 0.82 | MEN1 (0.61) | MAPTPOLBMEN1GAAKMT2A | |
| SCHEMBL3529132 | 0.76 | CYP1A2 (0.55) | MAPTPOLBMEN1GAAKMT2A | |
| SCHEMBL9541467 | 0.73 | MAPT (0.60) | MAPTPOLBMEN1GAAKMT2A | |
| SCHEMBL9538451 | 0.73 | MAPT (0.60) | MAPTPOLBMEN1GAAKMT2A | |
| SCHEMBL9379932 | 0.72 | MEN1 (0.64) | MAPTPOLBMEN1GAAKMT2A | |
| SCHEMBL32690204 | 0.71 | CYP1A2 (1.00) | MAPTPOLBMEN1GAAKMT2A | |
| SCHEMBL9537650 | 0.69 | MAPT (0.54) | MAPTPOLBMEN1GAAKMT2A | |
| SCHEMBL9184204 | 0.65 | NPC1 (0.54) | MAPTPOLBMEN1GAAKMT2A | |
| SCHEMBL14417581 | 0.65 | RAB9A (0.65) | MAPTPOLBMEN1GAAKMT2A | |
| SCHEMBL4283622 | 0.65 | MAPT (0.53) | MAPTPOLBMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167263-B2 | Treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2019-01-01 | — | — | US | disclosed |
| US-20170349552-A1 | Treatment of Amyotrophic Lateral Sclerosis | NORTHWESTERN UNIVERSITY (US) | 2017-12-07 | — | — | US | disclosed |
| US-9809556-B2 | Treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160016911-A1 | Treatment of Amyotrophic Lateral Sclerosis | NORTHWESTERN UNIVERSITY | 2016-01-21 | — | — | US | disclosed |
| US-20160016911-A1 | Treatment of Amyotrophic Lateral Sclerosis | NORTHWESTERN UNIVERSITY | 2016-01-21 | — | — | US | disclosed |
| US-9145424-B2 | Treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145424-B2 | Treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2015-09-29 | — | — | US | disclosed |
| US-20110237907-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237907-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016911-A1 | Treatment of Amyotrophic Lateral Sclerosis | SMN1; SMN2, SOD1, NLN | MAPT 16/4885POLB 2415/4885MEN1 4639/4885 |
| US-10167263-B2 | Treatment of amyotrophic lateral sclerosis | SMN1; SMN2, SOD1, NLN | MAPT 16/4885POLB 2415/4885MEN1 4639/4885 |
| US-20170349552-A1 | Treatment of Amyotrophic Lateral Sclerosis | SMN1; SMN2, SOD1, NLN | MAPT 16/4885POLB 2415/4885MEN1 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.